Top Tweets for #CheckMate914
Different results from 2 phase 3 studies on adjuvant IO for mRCC... what's the reason? - @DrIacovelli
@SuyogCancer
#ASCOGU24 #Cancer #Checkmate914 #KEYNOTE564 #MetastaticRenalCarcinoma #Ocnology #OncoDaily
https://t.co/sdtoxzAL1B
Adjuvant nivo monotherapy vs PBO for localized #RCC at high risk of relapse after nephrectomy: Results from part B of the randomized, phase 3 #CheckMate914 trial. Presentation by @motzermd @MSKCancerCenter. #GU24 coverage by @zklaassen_md @GACancerCenter > https://t.co/y5YC2BLaiQ
@motzermd with a thorough overview of the #Checkmate914 data, nivolumab without signif disease free survival effect vs placebo. <10% T4 or N1 and no M1NED pops may be a clue? @ASCO #GU24 @OncoAlert
The #OncoAlertTopTweet π¨
Day 4β£of #ASCO23 π
Tweet by our @OncoAlert faculty @DrChoueiri πΊπΈ
Masterful presentation by @motzermd reporting subgroup analyses from #CheckMate914 (part A). Exploratory analyses suggest tumor PD-L1 expression influenced outcome of adjuvant IPI+NIVO in pts with localized #RCC at high risk of post-nephrectomy relapse
Best, @weoncologists
Masterful presentation by @motzermd reporting subgroup analyses from #CheckMate914 (part A).
Exploratory analyses suggest tumor PD-L1 expression influenced outcome of adjuvant IPI+NIVO in pts with localized #RCC at high risk of post-nephrectomy relapse #ASCO23 @OncoAlert
@tbivala1 give his take home messages for the 1] #SWOGS1011 surgical trial of standard vs extended lymphadenectomy 2] the #VESPER trial of dd-MVAC vs GC as perioperative chemo for MIBC 3] #CheckMate914 Adjuvant Nivo/Ipi in high risk #RCC after nephrectomy @ASCO #ASCO23
![apolo_andrea's tweet photo. @tbivala1 give his take home messages for the 1] #SWOGS1011 surgical trial of standard vs extended lymphadenectomy 2] the #VESPER trial of dd-MVAC vs GC as perioperative chemo for MIBC 3] #CheckMate914 Adjuvant Nivo/Ipi in high risk #RCC after nephrectomy @ASCO #ASCO23 https://t.co/8PIFipbOvo](https://pbs.twimg.com/media/Fx4eR5pX0AAgXg7.jpg)
![apolo_andrea's tweet photo. @tbivala1 give his take home messages for the 1] #SWOGS1011 surgical trial of standard vs extended lymphadenectomy 2] the #VESPER trial of dd-MVAC vs GC as perioperative chemo for MIBC 3] #CheckMate914 Adjuvant Nivo/Ipi in high risk #RCC after nephrectomy @ASCO #ASCO23 https://t.co/8PIFipbOvo](https://pbs.twimg.com/media/Fx4eR5oXsAAntco.jpg)
![apolo_andrea's tweet photo. @tbivala1 give his take home messages for the 1] #SWOGS1011 surgical trial of standard vs extended lymphadenectomy 2] the #VESPER trial of dd-MVAC vs GC as perioperative chemo for MIBC 3] #CheckMate914 Adjuvant Nivo/Ipi in high risk #RCC after nephrectomy @ASCO #ASCO23 https://t.co/8PIFipbOvo](https://pbs.twimg.com/media/Fx4eR5jWIAE-twd.jpg)
#ASCO23 Concluding a great GU session moderated by @NehaVapiwala & @mkbupathi
β
#Checkmate914 adjuvant IPI/Nivo benefit some w #RCC
β
#VESPER ddMVAC better than GC for perioperative MIBC
βοΈ@SWOG extLND no benefit and more toxic in UC
@motzermd Seth Lerner, Cristian Pfister
Masterful presentation by @motzermd reporting subgroup analyses from #CheckMate914 (part A).
Exploratory analyses suggest tumor PD-L1 expression influenced outcome of adjuvant IPI+NIVO in pts with localized #RCC at high risk of post-nephrectomy relapse #ASCO23 @OncoAlert
Dr. @motzermd with an important presentation of #CHECKMATE914 Part A subgroup analyses.
@ASCO #ASCO23
While the overall trial showed no improved outcomes with the combination of Nivo/Ipi vs placebo, sarcomatoid, high grade, and PD-L1 positive patients seemed to derive benefit from adjuvant Nivo/Ipi.
@MSK_DeptOfMed @MSKCancerCenter @HemOncToday @HemOncFellows @Hemoncq @IMG_Oncologists @OncoAlert
@motzermd dives into the patient features, amount of treatment, and QOL of the phase 3 #CheckMate914 (part A) trial of Adjuvant Nivo/Ipi vs placebo for patients with localized high risk #RCC #renalcellcarcinoma after nephrectomy
@ASCO #ASCO23
Always a pleasure to record w @montypal as we re-hashed #ESMO22 β #PROSPER #IMMotion010 #Checkmate914 #COSMIC313 #EV103cohortK β give a listen @CancerDotNet!
https://t.co/V1116Fn8jc
π£ NEW PODCAST! @ILSONDavid @montypal and @TiansterZhang discuss #NewResearch from #ESMO22 in gastrointestinal and genitourinary cancers https://t.co/0WnMOcXJBz #CancerResearch #LiverCancer #ColorectalCancer #StomachCancer #KidneyCancer #BladderCancer and #ProstateCancer #CRCSM
Adjuvant nivolumab + ipilimumab vs PBO for localized #RCC at high risk of relapse after nephrectomy: results from the randomized, phase 3 #CheckMate914 trial. Presented by @motzermd @MSKCancerCenter. #ESMO22 written coverage by @WallisCJD @UofT > https://t.co/VfgTCznBk9 @myESMO
Surprising data from #Checkmate914 trial showing adjuvant ipi-nivo did not improve disease free survival for #kidneycancer. Grateful as always for the patients who participated to help us learn in this massive trial. #ESMO22 @myESMO @OncoAlert
Presidential-2 #ESMO22
Primary endpoint for phase 3 CM914 trial not met, nivo + ipi not superior to placebo--higher toxicity. No clear subgroups that benefit. Part-B: adjuvant nivo only is ongoing!
@motzermd
@myESMO @OncoAlert
A packed house to hear #JamesLarkin discuss perioperative #kidneycancer management! Highlighting populations w benefit in #Keynote564 and the 3 adjuvant/periop trials to look forward to at #ESMO22! #IMmotion010, #PROSPERRCC #Checkmate914
#ESMO22 is next week!! As always from @DrChoueiri, this list of GU oncology abstracts is high impact. Looking forward to #COSMIC313, #PROSPER, #IMmotion010, #Checkmate914, #EV103 cohort K, #PRO biomarkers, #PRESTO, and so much moreβ¦
As #ESMO22 is approaching, here are my list of Top 15 #GU Oncology presentations, just based on "Titles"...
This list may ultimately change after abstracts release
https://t.co/pJCTDQnzb4
@myESMO @KKronig @FedefedeFri
βοΈNegative results from #CheckMate914 Trial π« π₯²π€¦π»ββοΈ
Possible reasonβ¦.π€·π»ββοΈβ
- Not all anti PD1 are the same? (Nivo < Pembro)
- M1 pts in KN564 vs only M0 in CM914?
π§
Many other trials ongoing in #adjuvant #RCC⦠waiting for more data and more details!
JUST IN: adjuvant nivo+ipi (6 months) in high-risk RCC did not meet its primary endpoint of DFS. Press release by @bmsnews via @BusinessWire βBig News this am!
@OncoAlert
https://t.co/WtyFAMHQxl
#Nivolumab #Ipilimumab #CheckMate914 #ScienceLink
CCR localizado: Nivolumab + ipilimumab no alcanzaron objetivo primario de SLE, estudio CheckMate-914
https://t.co/TFwYHKXhFt
Last Seen Hashtags on Sotwe
agingneuroscience
Seen from United States
virginiafreaks
Seen from Argentina
prankstraight
Seen from Singapore
tiktok teens
Seen from Germany
FFToronto
Seen from Netherlands
humantoilet
Seen from Switzerland
momsonn
Seen from Switzerland
θ±γγΉ
Seen from United States
taksimgay
Seen from Turkey
ometv
Seen from Germany
Most Popular Users
Elon Musk 
@elonmusk
241.2M followers
Barack Obama
@barackobama
119.1M followers
Cristiano Ronaldo
@cristiano
112.9M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.1M followers
Rihanna
@rihanna
98.3M followers
NASA
@nasa
92.3M followers
Justin Bieber
@justinbieber
91.5M followers
KATY PERRY
@katyperry
89M followers
Taylor Swift
@taylorswift13
83M followers
Lady Gaga
@ladygaga
74.4M followers
Virat Kohli
@imvkohli
71.9M followers
Kim Kardashian
@kimkardashian
70.5M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
64.9M followers
Bill Gates
@billgates
64.6M followers
The Ellen Show
@theellenshow
62.4M followers
Selena Gomez
@selenagomez
62.1M followers
CNN
@cnn
61.8M followers
X
@x
60.8M followers